Xenon Pharmaceuticals Number of Employees 2012-2022 | XENE

Xenon Pharmaceuticals number of employees from 2012 to 2022. Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis
Xenon Pharmaceuticals Annual Number of Employees
2021 153
2020 129
2019 104
2018 92
2017 81
2016 94
2015 83
2014 74
2013 74
2012
2011
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.635B $0.018B
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of medicines through the application of its proprietary discovery platform, which it refer to as Extreme Genetics. Xenon is developing proprietary product candidates for the treatment of both orphan as well as more prevalent diseases. The company offers Glybera (R), a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan disorder. Xenon Pharmaceuticals Inc. is headquartered in Burnaby, Canada.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00